This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The Expected Rise and Inevitable Fall of MannKind

I was asked on Twitter last week to comment on the big move in MannKind (MNKD) shares recently, ahead of the expected FDA approval decision for Afrezza on July 15. The tweet below was my reply but I want to elaborate a bit more. Using Arena Pharmaceuticals (ARNA) (a very similar, retail-driven cult stock) as a precedent, MannKind should go even higher as we get closer to July 15, but if/when Afrezza is approved, the sell off begins.

MannKind (Afrezza, insulin, diabetes) and Arena (Belviq, obesity) are very similar companies. Each pulls a significant following from retail investors who are 1) rabid and devoted to their beloved companies; and 2) fervent believers in the multi-billion dollar revenue potential for their products. It's fair to describe both MannKind and Arena as battleground stocks for bulls and bears -- each has (or has had) a significant short position. And both companies have survived past FDA rejections and managed to win at subsequent FDA advisory panel meetings

Given the similarities, I thought we could learn something about MannKind's current stock behavior by looking back at what happened to Arena when Belviq was making its way through the FDA approval process. 

The chart below tracks Arena's stock price in May and June 2012. For those who might not remember, Belviq was reviewed by an FDA advisory panel on May 10, 2012. The experts on the panel voted to recommend the drug's approval for treating weight loss. As you can see, the positive FDA panel vote had a big impact on the value of Arena's stock.

Here are some specific numbers: From May 10 (the day of the Belviq panel) to the close of trading on May 11, Arena's stock price rose 74% (from $3.66 per share to $6.36 per share.) This 74% jump in Arena's stock price is represented by the almost-vertical spike on the left of the chart. 

After that initial bump, Arena's stock price continued higher heading into the FDA approval decision for Belviq on June 27, 2012. From May 11, 2012 to June 27, 2012, Arena's stock price rose another 80%, closing at $11.39 per share. On the night Arena executives and shareholders were celebrating Belviq's approval, the company sported an enterprise value of just over $2.25 billion.

ARNA Chart
ARNA data by YCharts

If MannKind and Arena are similar, trading in the two stocks around their respective FDA advisory panels and approval decisions should also be similar. And so they are! 

The chart below tracks MannKind shares this past March and April. The Afrezza FDA advisory panel was held on April 1. 

On April 1, MannKind's stock price was $4.02 per share. The FDA panel vote was positive, causing MannKind shares to close at $6.99 on April 2. That's a 74% increase in MannKind's stock price -- the exact same percentage increase as was seen with Arena following the Belviq panel. 

MNKD Chart
MNKD data by YCharts

If the same trading behavior seen with Arena holds for MannKind, the stock has more room to run into the Afrezza July 15 approval decision date. So far, that's exactly what MannKind shares have done. As you can see in the chart below, MannKind's current stock price has risen another 50% since April 2. If MannKind continues to mimic Arena (80% bump between panel and approval date), you could see MannKind shares reach $12 or $13 by July 15. 

MNKD Chart
MNKD data by YCharts


That's the good news for MannKind shareholders and speculative traders. However, if the Arena analogy holds, the Afrezza post-approval honeymoon will be brief. 

Remember above when I told you Arena's stock price reached $11.39 on the day Belviq was approved. Well, here's the Arena chart in the two years since. Not pretty. Arena has lost 45% of its value since the day Belviq was approved, mainly because the commercial launch has been a major disappointment. The billions of dollars in sales Arena bulls expected have not materialized, and will likely never materialize. 

ARNA Chart
ARNA data by YCharts

This is the point of the story where MannKind bulls will argue ferociously that their beloved stock is different from Arena and will not suffer the same post-approval slide. In some respects, they're right. Arena and MannKind are somewhat different, post the approval of their respective products. Unfortunately for MannKind bulls, Arena was actually in a stronger position. 

When Belviq was approved, Arena had a Big Pharma marketing partner in place. So far, MannKind is alone. Arena's balance sheet and cash position were strong. MannKind's current balance is racked with debt and the company's cash is running low. 

Belviq was approved with a clean, relatively unrestricted FDA label. Based on the comments from experts on the April 1 advisory panel, I won't be surprised to see FDA slaps significant restrictions on Mannkind's Afrezza label. Arena shares have suffered since Belviq's approval because the efficacy of the weight loss drug is mediocre, at best. MannKind faces similar problems with Afrezza's clinical profile.

MannKind's current enterprise value is approaching $4 billion and may reach $5 billion as July 15 approaches. When Belviq was approved, Arena's enterprise value was "just" $2.25 billion. 

I can't show you a chart of MannKind's stock price after July 15, but if history is a guide, look out below.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASDAQ 4,598.1880 +17.9170 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs